Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $27.13.

KURA has been the subject of several research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. Wedbush increased their price objective on shares of Kura Oncology from $34.00 to $36.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Bank of America dropped their price objective on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. BTIG Research downgraded shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st.

Kura Oncology Price Performance

Shares of NASDAQ:KURA opened at $8.25 on Tuesday. The company has a market cap of $641.21 million, a price-to-earnings ratio of -3.49 and a beta of 0.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm has a 50 day simple moving average of $8.30 and a 200 day simple moving average of $14.15. Kura Oncology has a one year low of $6.98 and a one year high of $24.17.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,729 shares of company stock valued at $92,307 over the last quarter. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

Large investors have recently bought and sold shares of the stock. nVerses Capital LLC acquired a new stake in Kura Oncology in the third quarter worth $25,000. Virtus ETF Advisers LLC grew its holdings in Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after purchasing an additional 3,061 shares during the period. Harbor Advisors LLC acquired a new stake in Kura Oncology in the fourth quarter worth $87,000. E Fund Management Co. Ltd. acquired a new stake in Kura Oncology in the fourth quarter worth $90,000. Finally, Corton Capital Inc. acquired a new stake in Kura Oncology in the fourth quarter worth $99,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.